A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

TY - JOUR

T1 - A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

AU - Mocroft, A

AU - Reiss, P

AU - Rakhmanova, A

AU - Banhegyi, D

AU - Phillips, A N

AU - De Wit, S

AU - Ristola, M

AU - Lundgren, J D

AU - Grarup, J

AU - Kirk, O

AU - EuroSIDA in EuroCoord

PY - 2014/8/1

Y1 - 2014/8/1

N2 - ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.

AB - ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.

KW - Adenine

KW - Adult

KW - Anti-HIV Agents

KW - Cohort Studies

KW - Data Collection

KW - Deoxycytidine

KW - Drug Combinations

KW - Drug Utilization

KW - Europe

KW - Female

KW - HIV Infections

KW - Humans

KW - Male

KW - Organophosphonates

KW - Oxazines

KW - Prospective Studies

U2 - 10.1007/s15010-014-0630-4

DO - 10.1007/s15010-014-0630-4

M3 - Journal article

C2 - 24902520

SN - 0300-8126

VL - 42

SP - 757

EP - 762

JO - Infection: A Journal of Infectious Diseases

JF - Infection: A Journal of Infectious Diseases

IS - 4

ER -